CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The RARITY project aims to enhance cancer immunotherapy by identifying and utilizing cancer-reactive T cells from non-immunogenic tumors. It focuses on developing new cancer antigens and understanding various immune cell roles to improve treatment outcomes for patients with limited options.
Checkpoint blockade immunotherapies have revolutionized cancer treatment.
However, this immunotherapy only benefits a minority of patients (< 15%), mainly those diagnosed with cancers having many mutations.
Furthermore, checkpoint blockade therapy does not selectively activate cancer-reactive T cells.RARITY responds to these shortcomings, aiming to provide innovative solutions for the development of effective immunotherapies for patients who do not benefit from current treatments.
The ground-bre…
Leiden University Medical Center
ACADEMISCH ZIEKENHUIS LEIDEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
